Infectious Vaccine Collaboration and Licensing Deals 2016-2024


Infectious Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 522 infectious vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of infectious vaccine dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in infectious vaccine dealmaking since 2016.

Chapter 3 provides an overview of the leading infectious vaccine deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in infectious vaccine dealmaking with a brief summary followed by a comprehensive listing of infectious vaccine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of infectious vaccine deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of infectious vaccine partnering deals signed and announced since Jan 2016. The chapter is organized by specific infectious vaccine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in infectious vaccine deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Infectious Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse infectious vaccine collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Infectious Vaccine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of infectious vaccine trends and structure of deals entered into by leading biopharma companies worldwide.

Infectious Vaccine Collaboration and Licensing Deals includes:
•    Trends in infectious vaccine dealmaking in the biopharma industry
•    Directory of infectious vaccine deal records covering pharmaceutical and biotechnology
•    The leading infectious vaccine deals by value
•    Most active infectious vaccine licensing dealmakers

Infectious Vaccine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Infectious Vaccine Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse infectious vaccine collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectious vaccine dealmaking
2.1. Introduction
2.2. Infectious vaccine deals over the years
2.3. Most active infectious vaccine dealmakers
2.4. Infectious vaccine deals by deal type
2.5. Infectious vaccine deals by therapy area
2.6. Infectious vaccine deals by industry sector
2.7. Deal terms for infectious vaccine deals
2.7.1 Infectious vaccine deals headline values
2.7.2 Infectious vaccine deal upfront payments
2.7.3 Infectious vaccine deal milestone payments
2.7.4 Infectious vaccine royalty rates

Chapter 3 – Leading infectious vaccine deals
3.1. Introduction
3.2. Top infectious vaccine deals by value

Chapter 4 – Most active infectious vaccine dealmakers
4.1. Introduction
4.2. Most active infectious vaccine dealmakers
4.3. Most active infectious vaccine deals company profiles

Chapter 5 – Infectious vaccine contracts dealmaking directory
5.1. Introduction
5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 – Infectious vaccine dealmaking by technology type

Deal directory

Deal directory – Infectious vaccine deals by company A-Z
Deal directory – Infectious vaccine deals by deal type
Deal directory – Infectious vaccine deals by therapy area

Deal type definitions

About Biopharma Research Ltd    
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Infectious vaccine deals since 2016
Figure 2: Active infectious vaccine dealmaking activity – 2016 - 2024
Figure 3: Infectious vaccine deals by deal type since 2016
Figure 4: Infectious vaccine deals by therapy area since 2016
Figure 5: Infectious vaccine deals by industry sector since 2016
Figure 6: Infectious vaccine deals with a headline value
Figure 7: Infectious vaccine deals with an upfront value
Figure 8: Infectious vaccine deals with a milestone value
Figure 9: Infectious vaccine deals with a royalty rate value
Figure 10: Top infectious vaccine deals by value since 2016
Figure 11: Most active infectious vaccine dealmakers 2016 - 2024
Figure 12: Infectious vaccine deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2A, A*STAR’ Institute of Molecular and Cell Biology, Abnova, AbVacc, Academy of Military Medical Sciences (China), AchilleS Vaccines, Adaptive Phage Therapeutics, AdaptVac, Aduro BioTech, Advaccine Biotechnology, Advanced BioNutrition, Advanced BioScience Laboratories, Aegis Life, Aelix Therapeutics, Aerogen, Affinivax, Afrigen Biologics, AGC Biologics, AIM ImmunoTech, Akers Biosciences, Akshaya Bio, Akston Biosciences, Aldevron, Algenex, Altimmune, American Gene Technologies, American Type Culture Collection (ATCC), Amyris, AnGes MG, Aphios, Appili Therapeutics, Applied DNA Sciences, Aragen Bioscience, Arcturus Therapeutics, Ardigen, Aridis Pharmaceuticals, Artes Biotechnology, Astellas Pharma, AstraZeneca, AuraVax Therapeutics, Aurobindo Pharma, Avid Bioservices, Barinthus Biotherapeutics, Batavia Biosciences, Battelle, Bavarian Nordic, Baylor College, Baylor College of Medicine, Beijing Minhai Biotechnology, Beth Israel Deaconess Medical Center, Bharat Biotech, BIA Separations, Bill and Melinda Gates Foundation, Binex, Bintai Kinden, BioComo, Biofabri, Biofactura, Biolexis, Biomedical Advanced Research and Development Authority, BiondVax, BioNet Holding, BioNTech, BioSun Pharmed, Biotechnology Industry Research Assistance Council, BioVaxys, Blackstone, Blanver, Blue Water Vaccines, BlueWillow Biologics, Botanical Solution, Bpifrance, BravoVax, Brickell Biotech, Brii Biosciences, BTG, Burnet Institute, Butantan Institute, California Institute for Regenerative Medicine, CanSinoBIO, Capricor Therapeutics, CARB-X, CaroGen, Catalent, Catholic University Leuven, CCT Research, Celdara Medical, Celonic, Centers for Disease Control and Prevention, Changchun BCHT Biotechnology, Chengdu Kanghua Biological Products, Children's Hospital Boston, Chimeron Bio, China National Biotech Group (CNBG), CimCure, Cincinnati Children’s Hospital Medical Center, CIRION BioPharma Research, Citranvi Biosciences, City College of New York, City of Hope, Clarametyx Biosciences, ClearPath, Clover Biopharmaceuticals, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Codagenix, Codiak BioSciences, Colombia Ministry of Health and Social Protection, Colorado State University, ConserV Bioscience, COVAXX, Cristal Therapeutics, Croda, Crozet BioPharma, CSIRO, CSL, Curapath, Curative Biotechnology, CureVac, CVC, CyanVac, Cystron Biotech, Cytiva, Cytovance Biologics, Dalton Pharma Services, Debiopharm, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Department of Defense, Department of Health and Human Services, DIOSynVax, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, Elixirgen, Emergent BioSolutions, Emergex Vaccines, Emmes, Emory University, EmVenio Research, Enesi Pharma, Ennaid Therapeutics, Entos Pharmaceuticals, Epivax, EpiVax Therapeutics, Epygen Biotech, eTheRNA immunotherapies, Ethris, Eurocine Vaccines, European Union, Evaxion Biotech, Everest Medicines, EVQLV, ExcellGene, Excivion, eXmoor Pharma, Exothera, ExpreS2ion Biotechnologies, Eyam Vaccines and Immunotherapeutics, Eyegene, Farmacore Biotechnology, Fatro, Federal Ministry of Education and Research (BMBF), Fina Biosolutions, Flow Pharma, FluGen, Food and Drug Administration (FDA), Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Gamaleya National Center, GC Pharma, GE Healthcare, Generex Biotechnology, Genetic Immunity, Genevant Sciences, Genexine, Gennova Biopharmaceuticals, Genocea Biosciences, Genomma Lab Internacional, George Mason University, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline Biologicals, Global Virus Network, Government of Canada, Government of India, Government of South Korea, Greenlight Biosciences, Greenwich LifeSciences, Gritstone Bio, GSK, GTP Bioways, HaloVax, HanaVax, Harro Hofliger, Harvard University, Hawaii Biotech, HDT Bio, Heat Biologics, Helocyte, Henry M. Jackson Foundation, HilleVax, Horizon Europe, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), hVIVO, Iaso Therapeutics, Icahn School of Medicine at Mount Sinai, Icon, Iconovo, Icosavax, IDT Biologika, ImmBio, Immune System Regulation, ImmunityBio, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoScape, Immunovaccine, Immuron, Imophoron, Imperial College London, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), Infor, InnoCentive, Innovate UK, Innovo, Inovio, Inovio Pharmaceuticals, Inserm Transfert, InSilicoTrials, Inspirevax, Institute for Bioscience and Biotechnology Research, Institut Pasteur, INTACT Solutions, Integral Molecular, Integrated BioTherapeutics, International AIDS Vaccine Initiative, International Vaccine Institute (IVI), Intravacc, IQVIA, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jenner Institute, JSC Pharmadis, Kansas State University, Karolinska Institute, KBI BioPharma, KELTIC Pharma, Kemin Industries, Kenya Medical Research Institute, Kermode Biotechnologies, King Abdullah University for Science and Technology, King Saud University, Kleo Pharmaceuticals, Korea Advanced Institute of Science and Technology, La Jolla Institute for Allergy & Immunology, Lawrence Livermore National Laboratory, Leidos, Leukocare, LimmaTech Biologics, LinKinVax, LiteVax, Longeveron, Lonza, Lumos Pharma, Macquarie University, Magnetrap, Maryland Technology Development Corporation, Massachusetts General Hospital, Massachusetts Institute of Technology, McMaster University, MedGene Bioscience, Medicago, Medical University of Vienna, MediciNova, MediGene, Medigen Vaccine Biologics, Medison Pharma, Medlab Clinical, Medytox, Mellow Hope Bio Chem, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Metaclipse Therapeutics, Mexican National Technology and Science Council, Micron Biomedical, Mid-Atlantic BioTherapeutics, Midatech Pharma, Mie University, MigVax, MilliporeSigma, MinervaX, Ministry of Health (Denmark), Moderna, MphRx, MSD Wellcome Trust Hilleman Laboratories, Mundo Sano, Mymetics, NanoBio, NanoPass Technologies, Nant Africa, NantKwest, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Cholera and Enteric Diseases, National Institute of Hygiene and Epidemiology, National Institute of Infectious Diseases, National Institute of Vaccines and Medical Biologicals, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, National Research Council Canada, National Research Council of Canada, National Science Foundation, Nature Technology, Navigo Proteins, New Zealand's Foundation for Research, Science and Technology, Nexelis, Noachis Terra, Nobelpharma, Novavax, Novo, NRx Pharmaceuticals, Nuance Pharma, NuGenerex Immuno-Oncology, Nykode Therapeutics, Ocugen, Ohio State University, Ology Bioservices, Omniose, Oragenics, Oramed Pharmaceuticals, Oravax Medical, OSE Immunotherapeutics, Osivax, Oswaldo Cruz Foundation (Fiocruz), Owkin, Oxgene, Pacific GeneTech, Panacea Biotech, PATH (Appropriate Technology in Health), PaxVax, PDS Biotechnology, Peter Doherty Institute for Infection and Immunity, Pfizer, PharmaJet, Pharma Science, Phil, PlantForm, PnuVax, Pohang University Of Science And Technology, POSCO International, Precision NanoSystems, Precision Virologics, Premas Biotech, Prestige BioPharma, ProBioGen, Probiomed, Profectus Biosciences, Prokarium, Protein Sciences, Provention Bio, Providence Therapeutics, PT Bio Farma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Quebec Government, Quratis, R-Pharm, Rabian, Ragon Institute, Rapid Dose Therapeutics, Rational Vaccines, Recipharm, Redbiotec, Refana, Regeneron Pharmaceuticals, ReiThera, Rentschler Biotechnologie, Repligen, Reyon Pharmaceuticals, Rockefeller University, RocketVax, Rokote Laboratories, Rubic One Health, Russian Direct Investment Fund, Sabin Vaccine Institute, Saiba, Samsung Biologics, Sanaria, Sanofi, Sanofi-Pasteur, Sartorius, Satio, Scandinavian Biopharma, Science 37, Scottish Enterprise, Scripps Research Institute, Selexis, Sementis, Senai Cimatec, Seoul National University, Seqirus, Serum Institute of India, Shionogi, Shionogi Pharma, Sinergium Biotech, Sinotek-Advocates International Industry Development, Sinovac Biotech, SK Bioscience, SmartPharm Therapeutics, Soligenix, Sorrento Therapeutics, Southern Research Institute, Spicona, SpyBiotech, St. Jude Children's Research Hospital, Stanford University, Strategic Vaccines, Sumaya Biotech, Sunstone Capital, SutroVax, Symvivo, Synairgen, Syngene International, Tabuk Pharmaceutical, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, Technical University of Denmark (DTU), TechnoVax, Texas A&M University, Texas Biomedical Research Institute, Texas Children’s Hospital, TFF Pharmaceuticals, The International AIDS Vaccine Initiative, The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Themis Bioscience, The Native Antigen Company, Therapyx, Thermo Fisher Scientific, Thomas Jefferson University, Tianjin CanSino Biotechnology, Tiba Biotech, TONIX Pharmaceuticals, Trans-Hit Bio, Translate Bio, Transtoxbio, Trianni, TriLink BioTechnologies, Tufts University, UK Government, UMN Pharma, United Nations Children Fund, Univercells, University Health Network, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of British Columbia, University of California, Davis, University of California Berkeley, University of Chicago, University of Edinburgh, University of Georgia, University of Hawaii, University of Houston, University of Liverpool, University of Maryland, University of Maryland School of Medicine, University of Miami, University of Miami Miller School of Medicine, University of Montreal, University of Nebraska, University of New South Wales, University of Oxford, University of Queensland, University of Saskatchewan, University of Southampton, University of Sydney, University of Tennessee, University of Texas, University of the Witwatersrand, University of Tokyo, University of Washington, University of Wisconsin-Madison, University of Zaragoza, US Air Force, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Biologic, US Department of Agriculture, US Government, Utrecht University, Vaccitech, Vaccizone, Vactech, Valneva, Valo Therapeutics, Variation Biotechnologies, VaxAlta, Vaxart, Vaxcyte, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, Vaxine, VaxNewMo, VaxThera, Vaxxas, VBI Vaccines, Veristat, Verndari, Versatope Therapeutics, Vinbiocare Biotechnology, Viravaxx, Vir Biotechnology, VitriVax, ViveBio, Voltron Therapeutics, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, Wellcome Trust, Westport Bio, Wipro, Xenetic Biosciences, Yale University, Zhifei Lvzhu Biopharmaceutical, Zolovax, Zuellig Pharma China, Zydus Cadila, ZYUS Life Sciences

urrent Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!